Med Parmasi Group (შპს მედ ფარმასი გრუპი)

Ratio	2018	2019	2020	2021	2022	2023	2024
Margins
Gross Margin	35.3%	35.0%	42.3%	41.1%	48.6%	40.8%	36.5%
EBITDA Margin	17.8%	14.3%	22.7%	8.2%	3.1%	-38.3%	-0.9%
EBITDAR	326	235	476	214	71	-565	-11
EBITDAR Margin	17.8%	14.3%	22.7%	8.2%	3.1%	-38.3%	-0.9%
EBIT Margin	16.3%	12.5%	21.3%	6.1%	0.8%	-42.5%	-6.1%
Net Profit Margin	12.5%	8.4%	17.1%	4.3%	0.6%	-39.5%	-4.1%
Operating Expense % of Sales	17.4%	20.7%	19.6%	32.9%	45.5%	79.1%	37.5%
Returns
Return on Assets (ROA)	13.7%	7.1%	16.9%	5.3%	0.9%	-54.9%	-5.4%
Return on Equity (ROE)	17.8%	9.7%	20.0%	6.0%	1.0%	-80.9%	-7.2%
ROIC [EBIT / Invested Capital]	19.1%	13.0%	23.4%	9.0%	1.6%	-84.9%	-10.7%
Leverage & debt balances
Debt-to-Assets	17.3%	15.0%	10.3%	2.3%	0.9%	2.7%	3.1%
Debt-to-Equity	0.22x	0.20x	0.12x	0.03x	0.01x	0.04x	0.04x
Debt-to-EBITDA	0.89x	1.24x	0.46x	0.23x	0.19x	N/A	N/A
Equity-to-Assets	76.9%	73.3%	84.1%	88.4%	85.6%	67.9%	75.3%
Net Debt	277	163	124	-124	-165	17	7
Cash & Equivalents	12	129	95	174	178	12	21
Total Debt	289	292	219	50	13	29	28
Liquidity & working capital
Current Ratio	4.75x	3.94x	4.88x	11.10x	6.58x	2.77x	3.03x
Quick Ratio	4.75x	2.50x	3.44x	9.07x	6.58x	2.77x	3.03x
Cash Ratio	0.06x	0.44x	0.39x	0.90x	1.01x	0.04x	0.10x
Total Current Assets	936	1,167	1,189	2,144	1,160	745	637
Total Current Liabilities	197	296	244	193	176	269	210
Inventory	N/A	425	352	393	N/A	N/A	N/A
Trade Receivables	685	534	651	597	431	240	340
Trade Payables	46	177	56	151	176	240	94
Net Working Capital	739	871	945	1,951	984	476	427
Net Working Capital % of Revenue	40.5%	52.9%	45.1%	74.7%	43.1%	32.3%	36.0%
Trade Working Capital	639	782	947	839	254	0	246
Trade Working Capital % of Revenue	35.0%	47.5%	45.2%	32.2%	11.1%	0.0%	20.7%
Change in Trade Working Capital	N/A	143	165	-108	-585	-254	245
Turnover & efficiency
Inventory Turnover	N/A	2.52x	3.44x	3.91x	N/A	N/A	N/A
Days Inventory Outstanding (DIO)	N/A	145.0	106.2	93.3	N/A	N/A	N/A
Receivables Turnover	2.66x	3.08x	3.21x	4.37x	5.30x	6.14x	3.49x
Days Sales Outstanding (DSO)	137.0	118.5	113.5	83.5	68.9	59.5	104.7
Payables Turnover	25.70x	6.05x	21.77x	10.21x	6.65x	3.64x	7.98x
Days Payable Outstanding (DPO)	14.2	60.3	16.8	35.7	54.9	100.2	45.7
Cash Conversion Cycle	122.8 days	203.2 days	203.0 days	141.1 days	14.0 days	-40.8 days	59.0 days
Asset Turnover	1.09x	0.85x	0.99x	1.22x	1.50x	1.39x	1.33x
Cash flow & dividends
Operating Cash Flow	-2	117	-34	79	4	-166	9
Free Cash Flow (OCF − Capex proxy)	-2	117	-34	79	4	-166	9
Cash Conversion (OCF / EBITDA)	-0.7%	49.8%	-7.2%	36.9%	5.6%	N/A	N/A
Dividends Declared	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividend Payout Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.

Med Parmasi Group

Shareholders

Directors & board

Key statistics

About

Revenue & margins

Financial statements

Ownership & group structure

Shareholders

Directors & board

Peers